Toyota|$17.91 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.06 (¥3,957)-2.78%▼ (in JPY terms)
SoftBank|$29.66 (¥4,682)+4.65%▲ (in JPY terms)
MUFG|$21.39 (¥3,377)+0.21%▲ (in JPY terms)
Keyence|$501.60 (¥79,190)+0.14%▲ (in JPY terms)
Nintendo|$52.64 (¥8,311)-1.68%▼ (in JPY terms)
NTT|$1.09 (¥172)-1.21%▼ (in JPY terms)
Takeda|$39.95 (¥6,307)-1.56%▼ (in JPY terms)
Tokyo Electron|$62.11 (¥9,805)+4.42%▲ (in JPY terms)
Recruit|$119.08 (¥18,800)+0.40%▲ (in JPY terms)
ITOCHU|$14.64 (¥2,311)-2.32%▼ (in JPY terms)
Honda|$11.16 (¥1,763)-1.45%▼ (in JPY terms)
Shin-Etsu|$38.03 (¥6,004)+2.63%▲ (in JPY terms)
Tokio Marine|$3.52 (¥555)-4.08%▼ (in JPY terms)
Fast Retailing|$465.68 (¥73,520)-0.33%▼ (in JPY terms)
Toyota|$17.91 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.06 (¥3,957)-2.78%▼ (in JPY terms)
SoftBank|$29.66 (¥4,682)+4.65%▲ (in JPY terms)
MUFG|$21.39 (¥3,377)+0.21%▲ (in JPY terms)
Keyence|$501.60 (¥79,190)+0.14%▲ (in JPY terms)
Nintendo|$52.64 (¥8,311)-1.68%▼ (in JPY terms)
NTT|$1.09 (¥172)-1.21%▼ (in JPY terms)
Takeda|$39.95 (¥6,307)-1.56%▼ (in JPY terms)
Tokyo Electron|$62.11 (¥9,805)+4.42%▲ (in JPY terms)
Recruit|$119.08 (¥18,800)+0.40%▲ (in JPY terms)
ITOCHU|$14.64 (¥2,311)-2.32%▼ (in JPY terms)
Honda|$11.16 (¥1,763)-1.45%▼ (in JPY terms)
Shin-Etsu|$38.03 (¥6,004)+2.63%▲ (in JPY terms)
Tokio Marine|$3.52 (¥555)-4.08%▼ (in JPY terms)
Fast Retailing|$465.68 (¥73,520)-0.33%▼ (in JPY terms)

admin

2026-10-27 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical Factory has launched a new product, "Hynex® Egel 1.5," a concentrated liquid food with a calorie concentration of 1.5 kcal/mL, designed to accommodate dietary restrictions on intake and fluid intake.”

by

2026-10-27 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical Factory has launched a new product, "Hyn … 続きを読む

2026-10-27 DAIICHI SANKYO COMPANY,LIMITED “Notice of Partial Approval for Enhertu® (trastuzumab deruxtecan) Regarding Postoperative Drug Therapy for HER2-Positive Early Breast Cancer in the EU (263.1KB) PDF file will be displayed in a new window.”

by

2026-10-27 DAIICHI SANKYO COMPANY,LIMITED “Notice of Partial Approval for Enhertu® (trastuzumab deruxtec … 続きを読む

2026-10-27 Astellas Pharma Inc. “VEOZA™ (fezolinenant) has been submitted for new drug approval by the Drug Evaluation Center of the National Medical Products Administration of China as a treatment for moderate to severe vasomotor symptoms associated with menopause.”

by

2026-10-27 Astellas Pharma Inc. “VEOZA™ (fezolinenant) has been submitted for new drug approval by the D … 続きを読む

Contact